PEDIATRICS Vol. 107 No. 5 May 2001, pp. 1147-1154
REVIEW ARTICLE:
An Assessment of Thimerosal Use in Childhood Vaccines
From the * Division of Vaccines and Related Products
Applications, Office of Vaccines Research and Review, and the
Division of Epidemiology, Office of Biostatistics and Epidemiology,
Center for Biologics Evaluation and Research, Food and Drug
Administration, Rockville, Maryland.
Background. On July 7, 1999, the American Academy of Pediatrics and the US Public Health Service issued a joint statement calling for removal of thimerosal, a mercury-containing preservative, from vaccines. This action was prompted in part by a risk assessment from the Food and Drug Administration that is presented here.
Methods. The risk assessment consisted of hazard identification, dose-response assessment, exposure assessment, and risk characterization. The literature was reviewed to identify known toxicity of thimerosal, ethylmercury (a metabolite of thimerosal) and methylmercury (a similar organic mercury compound) and to determine the doses at which toxicity occurs. Maximal potential exposure to mercury from vaccines was calculated for children at 6 months old and 2 years, under the US childhood immunization schedule, and compared with the limits for mercury exposure developed by the Environmental Protection Agency (EPA), the Agency for Toxic Substance and Disease Registry, the Food and Drug Administration, and the World Health Organization.
Results. Delayed-type hypersensitivity reactions from thimerosal exposure are well-recognized. Identified acute toxicity from inadvertent high-dose exposure to thimerosal includes neurotoxicity and nephrotoxicity. Limited data on toxicity from low-dose exposures to ethylmercury are available, but toxicity may be similar to that of methylmercury. Chronic, low-dose methylmercury exposure may cause subtle neurologic abnormalities. Depending on the immunization schedule, vaccine formulation, and infant weight, cumulative exposure of infants to mercury from thimerosal during the first 6 months of life may exceed EPA guidelines.
Conclusion. Our review revealed no evidence of harm caused by doses of thimerosal in vaccines, except for local hypersensitivity reactions. However, some infants may be exposed to cumulative levels of mercury during the first 6 months of life that exceed EPA recommendations. Exposure of infants to mercury in vaccines can be reduced or eliminated by using products formulated without thimerosal as a preservative. Key words: thimerosal, thiomersal, merthiolate, vaccine, immunization, mercury, methylmercury, ethylmercury, adverse event, risk assessment.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Woods Thimerosal & Neuropsychological Injury: Doubtful AAP Grand Rounds, May 1, 2009; 21(5): 49 - 49. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Tozzi, P. Bisiacchi, V. Tarantino, B. De Mei, L. D'Elia, F. Chiarotti, and S. Salmaso Neuropsychological Performance 10 Years After Immunization in Infancy With Thimerosal-Containing Vaccines Pediatrics, February 1, 2009; 123(2): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Baker Mercury, Vaccines, and Autism: One Controversy, Three Histories Am J Public Health, February 1, 2008; 98(2): 244 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Berman, I. N. Pessah, P. R. Mouton, D. Mav, and J. Harry Low-Level Neonatal Thimerosal Exposure: Further Evaluation of Altered Neurotoxic Potential in SJL Mice Toxicol. Sci., February 1, 2008; 101(2): 294 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Pichichero, A. Gentile, N. Giglio, V. Umido, T. Clarkson, E. Cernichiari, G. Zareba, C. Gotelli, M. Gotelli, L. Yan, et al. Mercury Levels in Newborns and Infants After Receipt of Thimerosal-Containing Vaccines Pediatrics, February 1, 2008; 121(2): e208 - e214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fombonne Thimerosal Disappears but Autism Remains Arch Gen Psychiatry, January 1, 2008; 65(1): 15 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Thompson, C. Price, B. Goodson, D. K. Shay, P. Benson, V. L. Hinrichsen, E. Lewis, E. Eriksen, P. Ray, S. M. Marcy, et al. Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years N. Engl. J. Med., September 27, 2007; 357(13): 1281 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agrawal, P. Kaushal, S. Agrawal, S. Gollapudi, and S. Gupta Thimerosal induces TH2 responses via influencing cytokine secretion by human dendritic cells J. Leukoc. Biol., February 1, 2007; 81(2): 474 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Fombonne, R. Zakarian, A. Bennett, L. Meng, and D. McLean-Heywood Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations Pediatrics, July 1, 2006; 118(1): e139 - e150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Baley and E. G. Leonard The Immunologic Basis for Neonatal Immunizations NeoReviews, October 1, 2005; 6(10): e463 - e470. [Full Text] [PDF]
|
|
|
|
|
|
J. Heron, J. Golding, and and the ALSPAC Study Team Thimerosal Exposure in Infants and Developmental Disorders: A Prospective Cohort Study in the United Kingdom Does Not Support a Causal Association Pediatrics, September 1, 2004; 114(3): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Bale JR Topical Review: Neurologic Complications of Immunization J Child Neurol, June 1, 2004; 19(6): 405 - 412. [Abstract] [PDF]
|
|
|
|
 |
|
 E. T. Luman, A. E. Fiore, T. W. Strine, and L. E. Barker Impact of Thimerosal-Related Changes in Hepatitis B Vaccine Birth-Dose Recommendations on Childhood Vaccination Coverage JAMA, May 19, 2004; 291(19): 2351 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Verstraeten, R. L. Davis, F. DeStefano, T. A. Lieu, P. H. Rhodes, S. B. Black, H. Shinefield, R. T. Chen, and for the Vaccine Safety Datalink Team Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases Pediatrics, November 1, 2003; 112(5): 1039 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Clarkson, L. Magos, and G. J. Myers The Toxicology of Mercury -- Current Exposures and Clinical Manifestations N. Engl. J. Med., October 30, 2003; 349(18): 1731 - 1737. [Full Text] [PDF]
|
|
|
|
|
|
A. Hviid, M. Stellfeld, J. Wohlfahrt, and M. Melbye Association Between Thimerosal-Containing Vaccine and Autism JAMA, October 1, 2003; 290(13): 1763 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Madsen, M. B. Lauritsen, C. B. Pedersen, P. Thorsen, A.-M. Plesner, P. H. Andersen, and P. B. Mortensen Thimerosal and the Occurrence of Autism: Negative Ecological Evidence From Danish Population-Based Data Pediatrics, September 1, 2003; 112(3): 604 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Baskin, H. Ngo, and V. V. Didenko Thimerosal Induces DNA Breaks, Caspase-3 Activation, Membrane Damage, and Cell Death in Cultured Human Neurons and Fibroblasts Toxicol. Sci., August 1, 2003; 74(2): 361 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Geier and D. A. Geier Neurodevelopmental Disorders after Thimerosal-Containing Vaccines: A Brief Communication Experimental Biology and Medicine, June 1, 2003; 228(6): 660 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Biroscak, A. E. Fiore, N. Fasano, P. Fineis, M. P. Collins, and G. Stoltman Impact of the Thimerosal Controversy on Hepatitis B Vaccine Coverage of Infants Born to Women of Unknown Hepatitis B Surface Antigen Status in Michigan Pediatrics, June 1, 2003; 111(6): e645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Coleman Ethylmercury in Vaccines Pediatrics, April 1, 2003; 111(4): 922 - 923. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Newschaffer, D. Fallin, and N. L. Lee Heritable and Nonheritable Risk Factors for Autism Spectrum Disorders Epidemiol. Rev., December 1, 2002; 24(2): 137 - 153. [Full Text] [PDF]
|
|
|
|
 |
|
 B Thjodleifsson, K Davidsdottir, U Agnarsson, G Sigthorsson, M Kjeld, and I Bjarnason Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine Gut, December 1, 2002; 51(6): 816 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Comstock Snippets from the Past: 70 Years Ago in the Journal Am. J. Epidemiol., November 15, 2001; 154(10): 951 - 953. [Full Text] [PDF]
|
|
|
|
|
|
N. A. Halsey and L. Goldman Balancing Risks and Benefits: Primum non nocere Is Too Simplistic Pediatrics, August 1, 2001; 108(2): 466 - 467. [Full Text]
|
|
